Effect of novel AC1 inhibitor in acute persistent and chronic muscle inflammation. A. Novel AC1 inhibitor NB001 produced significant reduction of licking responses in the late phase of the formalin test with peak response at 1 mg/kg body weight. n = 6 mice;p < 0.05. *Significant difference from vehicle. B. Effect of AC1 inhibitor NB001 on mechanical allodynia after chronic muscle inflammation. n = 4 mice; p < 0.05. *Significant difference from vehicle.